Major Depressive Disorder Clinical Trial
Official title:
Placebo-controlled, Dose-response Study of Ibuprofen Effects on Brain Function
The aim of this project is to determine whether the acute oral administration of Ibuprofen changes the activation pattern in the amygdala and other brain structures during functional magnetic resonance imaging. The investigators use a double-blind, randomized, repeated-measures design. Each of the 20 healthy control subjects will be tested three times and receive placebo, 200 mg or 600 mg dose of ibuprofen p.o. The study will consist of 4 sessions: a baseline screening session and 3 testing sessions scheduled 1-2 weeks apart. Each of these individuals will undergo a multi-level assessment based on the RDoC approach that consists of (a) a standardized diagnostic assessment, (b) self-report questionnaires assessing the positive and negative valence domains as well as interoception, (c) behavioral tasks assessing reward-related processing, avoidance, and aversive processing, cognition, and interoception; (d) physiological measurements consisting of facial emotion expression monitoring, heart rate and respiration, (e) functional magnetic resonance imaging focusing on reward-related processing, fear conditioning and extinction, cognitive inhibition, and interoceptive processing, and (f) biomarker assessments.
Occasional OTC nonsteroidal anti-inflammatory drugs (NSAID) use is prevalent in the United
States (25% aspirin, 9% ibuprofen, and 2% naproxen). An estimated 36 million Americans use
over-the-counter (OTC) analgesics daily, however, considering the widespread use of analgesic
agents, the overall incidence of serious drug-drug interactions involving these agents has
been relatively low. Neuroinflammatory mechanisms have been implicated in depression, and
NSAIDs have been found effective in animal models of depression both in monotherapy and when
used to augment antidepressant drugs. However, results with NSAIDs have been mixed in human
observational studies, with both better and worse depression outcomes reported. In animal
studies, mice injected with BCG showed an increase in the total immobility time during the
forced swim test (FST) and the tail suspension test (TST) and an increase in cerebral PGE2
and NO levels. Ibuprofen decreased the total immobility time during FST and TST and decreased
cerebral PGE2 and NO levels, which was comparable to fluoxetine's effect. This would suggest
that ibuprofen might have an antidepressant effect through inhibition of PGE2 and NO
production.
Some studies have demonstrated the success of augmentation of antidepressant therapy with
nonsteroidal anti-inflammatory drugs (NSAID) in decreasing depressive symptoms. However,
little is known about the benefit of NSAID therapy on depressive symptoms. In a recent
meta-analysis, using multivariable regression analysis a detectable effect in lowering PHQ-9
score in the ibuprofen or naproxen group (-0.31) and Celebrex group (-0.61) (p= .0390) was
observed. However, in a study with cognitively normal volunteers age 70 and older with a
family history of Alzheimer-like dementia who were randomly assigned to receive celecoxib 200
mg twice daily, naproxen sodium 220 mg twice daily, or placebo the investigators found no
treatment effect on geriatric depression scores over time in the subgroup of participants
with significant depressive symptoms at baseline. Moreover, there is some concern that
anti-inflammatory drugs inhibit the antidepressant effects of SSRIs. In the only published
fMRI study, ten healthy subjects underwent a double-blind, placebo-controlled, randomized,
cross-over phFMRI study with somatosensory painful stimulation of the right median nerve.
These authors reported a task-related increase of BOLD signal between drug and placebo in the
primary somatosensory area and the middle frontal gyrus that was not related to changes in
subjective pain scores. Thus there is some evidence that ibuprofen influences the BOLD
response in specific pain-related brain areas. Taken together, there is mixed evidence for
the effect of ibuprofen on mood and no data on its effect on the emotion circuitry.
Hypotheses:
1. The activation pattern in the amygdala during risk-taking decision-making will be
attenuated by ibuprofen in a dose dependent manner.
2. The activation pattern in the amygdala during anticipatory emotional arousal will be
attenuated by ibuprofen in a dose dependent manner.
3. The activation pattern in the amygdala during emotional face processing will be
attenuated by ibuprofen in a dose dependent manner.
4. The behavioral response during tasks assessing emotional and cognitive processes
including positive and negative valence and reward based learning will be modulated by
ibuprofen in a dose dependent manner.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 |